NEWTOWN, Pa.- Quinnova Pharmaceuticals, Inc. announced today the launch of Salvax™ Duo, which contains one unit of Salvax™ Foam (containing 6% salicylic acid) and one unit of Hydro 40® Foam (containing 40% urea). Salvax™ Duo is available by prescription only and both Salvax™ Foam and Hydro 40® Foam are indicated for hyperkeratotic conditions such as dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma and dry, rough skin, as well as corns and calluses. Additionally, both products use Quinnova’s patented Proderm Technology™, a water-lipid based formulation that has anti-inflammatory, skin repair and protective properties.
“In our continued effort to provide physicians and patients with added value in the treatment and maintenance of a variety of hyperkeratotic conditions, we are pleased to introduce Salvax™ Duo to the market,” said Jeffrey S. Day, Quinnova’s President and CEO. “Containing Salvax™ Foam and Hydro 40® Foam, with both of these products sharing the therapeutic, cosmetic and ease-of-use advantages of Proderm Technology™, we hope Salvax™ Duo becomes a 'go to' product for the treatment of chronic cases of hyperkeratotic conditions.”
The water-lipid nature of the Proderm Technology™ allows for the ingredients to be rapidly absorbed and incorporated into the outer layers of the skin. Furthermore, the Proderm Technology™ is non-comedogenic and provides a cosmetically elegant feel in addition to ease of application because it is non-greasy and spreads easily. Unlike some topical foam preparations, Proderm Technology™ does not use either alcohol or other organic solvents, therefore it is well tolerated by patients.
Quinnova Pharmaceuticals’ sales force calls on dermatologists and podiatrists across the United States.
